Verona Pharma logo

VRP - Verona Pharma Share Price

69p -2.5  -3.5%

Last Trade - 18/09/20

Small Cap
Market Cap £296.2m
Enterprise Value £278.8m
Revenue £n/a
Position in Universe 652nd / 1806
Unlock VRP Revenue
Relative Strength (%)
1m -13.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Verona Pharma Plc revenues was not reported. Net loss increased 18% to ¬£16.9M. Higher net loss reflects General and administrative costs increase of 92% to ¬£7.6M (expense), Effective G/L on Derivatives - Hedging decrease of 89% to ¬£184K (income), Foreign Exchange Gain/Loss‚ÄďNon-Busines decrease of 60% to ¬£267K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -¬£0.14 to -¬£0.16.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for VRP
Graphical History


VRP Revenue Unlock VRP Revenue

Net Income

VRP Net Income Unlock VRP Revenue

Normalised EPS

VRP Normalised EPS Unlock VRP Revenue

PE Ratio Range

VRP PE Ratio Range Unlock VRP Revenue

Dividend Yield Range

VRP Dividend Yield Range Unlock VRP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRP EPS Forecasts Unlock VRP Revenue
Profile Summary

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company is developing ensifentrine, the treatment for respiratory disease. Ensifentrine is an inhaled therapy that acts as both a bronchodilator and an anti-inflammatory agent in one compound. In addition to nebulized ensifentrine, the Company has developed dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) formulations of ensifentrine for less severe patients. The Company’s subsidiaries include Verona Pharma Inc. and Rhinopharma Limited.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 24, 2005
Public Since March 30, 2005
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 462,367,190
Free Float (0.0%)
Eligible for
VRP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VRP
Upcoming Events for VRP
Frequently Asked Questions for Verona Pharma
What is the Verona Pharma share price?

As of 18/09/20, shares in Verona Pharma are trading at 69p, giving the company a market capitalisation of £296.2m. This share price information is delayed by 15 minutes.

How has the Verona Pharma share price performed this year?

Shares in Verona Pharma are currently trading at 69p and the price has moved by 48.96% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verona Pharma price has moved by 77.48% over the past year.

What are the analyst and broker recommendations for Verona Pharma?

Of the analysts with advisory recommendations for Verona Pharma, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Verona Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Verona Pharma next release its financial results?

Verona Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Verona Pharma dividend yield?

Verona Pharma does not currently pay a dividend.

Does Verona Pharma pay a dividend?

Verona Pharma does not currently pay a dividend.

When does Verona Pharma next pay dividends?

Verona Pharma does not currently pay a dividend.

How do I buy Verona Pharma shares?

To buy shares in Verona Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Verona Pharma?

Shares in Verona Pharma are currently trading at 69p, giving the company a market capitalisation of £296.2m.

Where are Verona Pharma shares listed? Where are Verona Pharma shares listed?

Here are the trading details for Verona Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: VRP
What kind of share is Verona Pharma?

Based on an overall assessment of its quality, value and momentum, Verona Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Verona Pharma share price forecast 2020?

Shares in Verona Pharma are currently priced at 69p. At that level they are trading at 81.82% discount to the analyst consensus target price of 379.54.

Analysts covering Verona Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.217 for the next financial year.

How can I tell whether the Verona Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verona Pharma. Over the past six months, the relative strength of its shares against the market has been 76.77%. At the current price of 69p, shares in Verona Pharma are trading at 31.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Verona Pharma PE Ratio?

We were not able to find PE ratio data for Verona Pharma.

Who are the key directors of Verona Pharma?

Verona Pharma's management team is headed by:

Ben Harber - SEC
David Ebsworth - NEC
Kenneth Cunningham - NED
Anders Ullman - NED
Vikas Sinha - NED
Tara Rheault - VRD
Martin Edwards - NID
David Moskowitz - VPR
David Zaccardelli - PRE
Mark Hahn - CFO
Who are the major shareholders of Verona Pharma?

Here are the top five shareholders of Verona Pharma based on the size of their shareholding:

Access Industries Holdings, L.L.C. Corporation
Percentage owned: 10.73% (44.4m shares)
Arix Capital Management Limited Investment Advisor
Percentage owned: 3.23% (3.40m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 1.56% (6.46m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 1.28% (5.30m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 1.13% (4.67m shares)
Similar to VRP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.